Prognostic score for 2-year outcome after alloHSCT in CN-AML
| . | N . | LFS (% ± SE) . | OS (% ± SE) . | CIR (% ± SE) . | NRM (% ± SE) . |
|---|---|---|---|---|---|
| 0 factors | 104 | 79 ± 4 | 88 ± 3 | 14 ± 4 | 7 ± 3 |
| 1 factor | 322 | 73 ± 3 | 77 ± 2 | 15 ± 2 | 12 ± 2 |
| 2 or 3 factors | 223 | 50 ± 4 | 53 ± 4 | 31 ± 3 | 20 ± 2 |
| P | .002 | .003 | .0002 | .01 |
| . | N . | LFS (% ± SE) . | OS (% ± SE) . | CIR (% ± SE) . | NRM (% ± SE) . |
|---|---|---|---|---|---|
| 0 factors | 104 | 79 ± 4 | 88 ± 3 | 14 ± 4 | 7 ± 3 |
| 1 factor | 322 | 73 ± 3 | 77 ± 2 | 15 ± 2 | 12 ± 2 |
| 2 or 3 factors | 223 | 50 ± 4 | 53 ± 4 | 31 ± 3 | 20 ± 2 |
| P | .002 | .003 | .0002 | .01 |
SE, standard error.
Presence of Flt3-ITD, age > median, and >1 course of chemotherapy to reach CR1 were included as risk factors.